| Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
|---|---|---|---|---|---|
| Novartis | 1551 | 1023 | 100.0% | 341 | major |
| GlaxoSmithKline | 1202 | 734 | 100.0% | 379 | major |
| Pfizer | 917 | 598 | 99.2% | 239 | major |
| Merck Sharp & Dohme (MSD) | 873 | 527 | 100.0% | 219 | major |
| Roche | 808 | 441 | 98.2% | 205 | major |
| Sanofi S.A. | 774 | 413 | 99.8% | 298 | major |
| Astrazeneca | 750 | 441 | 97.5% | 145 | major |
| Johnson & Johnson | 594 | 353 | 98.9% | 153 | major |
| Eli Lilly | 494 | 333 | 98.2% | 86 | major |
| Medical University of Vienna | 462 | 304 | 91.4% | 84 | major |
| Amsterdam UMC | 420 | 103 | 30.1% | 77 | major |
| Bristol-Myers Squibb | 412 | 231 | 100.0% | 105 | major |
| Hospitals of Paris (AP-HP) | 407 | 92 | 18.5% | 75 | major |
| Boehringer Ingelheim | 400 | 322 | 100.0% | 50 | major |
| Bayer | 347 | 269 | 100.0% | 50 | major |
| Amgen Inc | 309 | 208 | 100.0% | 61 | major |
| KU Leuven | 288 | 238 | 94.5% | 16 | major |
| Novo Nordisk | 284 | 197 | 100.0% | 48 | major |
| Radboud University Medical Centre | 274 | 125 | 70.4% | 71 | major |
| Gilead Sciences Inc | 271 | 178 | 99.4% | 71 | major |
| Abbvie | 271 | 147 | 99.3% | 71 | major |
| Rigshospitalet | 270 | 174 | 61.5% | 26 | major |
| Takeda | 265 | 165 | 100.0% | 66 | major |
| No Sponsor Name Given | 254 | 100 | 60.0% | 37 | major |
| UCB | 241 | 128 | 98.4% | 93 | major |
| Erasmus University | 241 | 42 | 33.3% | 39 | major |
| Aarhus University | 224 | 154 | 71.4% | 13 | major |
| Charité-Universitätsmedizin Berlin | 214 | 180 | 97.2% | 9 | major |
| Agostino Gemelli University Polyclinic | 199 | 31 | 6.5% | 146 | major |
| University of Groningen | 192 | 26 | 46.2% | 22 | major |
| Leiden University | 184 | 21 | 33.3% | 32 | major |
| Merck KGaA | 179 | 134 | 100.0% | 27 | major |
| Utrecht University | 171 | 35 | 48.6% | 47 | major |
| IRCCS Ospedale San Raffaele | 167 | 70 | 81.4% | 68 | major |
| University College London | 163 | 90 | 98.9% | 10 | major |
| Astellas | 160 | 113 | 100.0% | 34 | major |
| Ghent University | 158 | 93 | 79.6% | 54 | major |
| Servier Laboratories | 154 | 120 | 100.0% | 19 | major |
| Celgene | 150 | 81 | 100.0% | 37 | major |
| Allergan | 147 | 108 | 98.1% | 30 | major |
| University of Oxford | 146 | 86 | 100.0% | 0 | major |
| Imperial College London | 145 | 103 | 100.0% | 3 | major |
| Medical University of Graz | 140 | 118 | 92.4% | 9 | major |
| Biogen | 140 | 92 | 96.7% | 31 | major |
| Karolinska University Hospital | 140 | 39 | 30.8% | 17 | major |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 135 | 89 | 16.9% | 38 | major |
| Novartis Vaccines | 132 | 65 | 100.0% | 63 | major |
| Eisai Inc. | 131 | 70 | 100.0% | 48 | major |
| Helsinki University | 129 | 68 | 22.1% | 31 | major |
| Oslo University Hospital | 125 | 40 | 37.5% | 37 | major |
| Pierre Fabre S.A. | 122 | 100 | 98.0% | 9 | major |
| Odense University Hospital | 120 | 83 | 91.6% | 16 | major |
| University of Birmingham | 118 | 53 | 100.0% | 10 | major |
| Chiesi Farmaceutici S.p.A | 117 | 80 | 100.0% | 24 | major |
| Vertex Pharmaceuticals, Inc. | 117 | 64 | 100.0% | 37 | major |
| Hospices Civils de Lyon | 117 | 40 | 20.0% | 18 | major |
| Shire | 115 | 80 | 100.0% | 24 | major |
| European Organisation for the Research and Treatment of Cancer (EORTC) | 111 | 72 | 94.4% | 21 | major |
| Abbott | 109 | 87 | 96.6% | 18 | major |
| King’s College London | 108 | 73 | 100.0% | 7 | major |
| Université libre de Bruxelles | 108 | 70 | 35.7% | 17 | major |
| Ipsen | 106 | 65 | 100.0% | 24 | major |
| National Cancer Institute Italy (Istituto Nazionale dei Tumori) | 106 | 35 | 5.7% | 28 | major |
| Herlev and Gentofte Hospital | 105 | 70 | 71.4% | 13 | major |
| Teva | 100 | 81 | 98.8% | 14 | major |
| Actelion Pharmaceuticals Ltd | 99 | 68 | 100.0% | 25 | major |
| H. Lundbeck A/S | 95 | 76 | 98.7% | 13 | major |
| Regeneron Pharmaceuticals Inc. | 94 | 41 | 100.0% | 30 | major |
| Unicancer | 93 | 33 | 72.7% | 9 | major |
| CSL Behring | 90 | 53 | 100.0% | 31 | major |
| Karolinska Institutet | 90 | 47 | 87.2% | 9 | major |
| Incyte Corporation | 89 | 32 | 90.6% | 26 | major |
| Daiichi Sankyo | 86 | 50 | 100.0% | 23 | major |
| Alexion Pharmaceuticals, Inc | 86 | 41 | 97.6% | 32 | major |
| Maastricht University | 86 | 31 | 35.5% | 30 | major |
| University of Munich (Ludwig-Maximilians) | 85 | 53 | 69.8% | 7 | major |
| Otsuka | 84 | 58 | 100.0% | 19 | major |
| Fundació Clínic per a la Recerca Biomèdica | 84 | 9 | 44.4% | 35 | major |
| University of Cologne | 82 | 60 | 96.7% | 2 | major |
| Innsbruck Medical University | 82 | 57 | 89.5% | 10 | major |
| Guy's and St Thomas' NHS Foundation Trust | 82 | 50 | 98.0% | 3 | major |
| CHU de Toulouse | 82 | 26 | 11.5% | 18 | major |
| Antoni van Leeuwenhoek Hospital | 82 | 11 | 36.4% | 9 | major |
| Vrije Universiteit Brussel | 81 | 36 | 61.1% | 12 | major |
| Genentech | 80 | 61 | 100.0% | 11 | major |
| Alcon | 76 | 44 | 100.0% | 31 | major |
| University of Dundee | 74 | 69 | 100.0% | 1 | major |
| Vall d'Hebron University Hospital | 73 | 23 | 82.6% | 17 | major |
| European Institute of Oncology | 73 | 12 | 0.0% | 28 | major |
| Menarini Group | 72 | 59 | 100.0% | 7 | major |
| University of Leeds | 72 | 52 | 98.1% | 0 | major |
| Technical University of Munich | 72 | 49 | 95.9% | 13 | major |
| University Hospital Tübingen | 72 | 49 | 85.7% | 4 | major |
| Bispebjerg Hospital | 71 | 58 | 56.9% | 6 | major |
| NHS Greater Glasgow and Clyde | 71 | 40 | 100.0% | 2 | major |
| CHU de Bordeaux | 71 | 14 | 28.6% | 14 | major |
| LEO Pharma A/S | 70 | 56 | 100.0% | 12 | major |
| CHU Clermont-Ferrand | 70 | 20 | 0.0% | 10 | major |
| Galderma R&D | 69 | 57 | 98.2% | 8 | major |
| The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 56 | 94.6% | 1 | major |
| Heidelberg University Hospital | 68 | 44 | 88.6% | 5 | major |
| Hospital de la Santa Creu i Sant Pau | 67 | 12 | 66.7% | 13 | major |
| ACCORD (University of Edinburgh & NHS Lothian) | 66 | 44 | 97.7% | 3 | major |
| Cliniques Universitaires Saint-Luc | 66 | 23 | 82.6% | 30 | major |
| AOU Citta Della Salute e Della Scienza di Torino | 66 | 1 | 0.0% | 10 | major |
| Queen Mary University of London | 65 | 43 | 100.0% | 4 | major |
| Baxter | 64 | 49 | 95.9% | 8 | major |
| University Erlangen-Nuremberg | 64 | 38 | 81.6% | 6 | major |
| Gothenburg University | 64 | 26 | 23.1% | 15 | major |
| University of Nottingham | 63 | 57 | 100.0% | 2 | major |
| Manchester University NHS Foundation Trust | 63 | 53 | 100.0% | 1 | major |
| Mario Negri Institute | 63 | 37 | 91.9% | 17 | major |
| University of Turku | 63 | 29 | 34.5% | 10 | major |
| Almirall S.A. | 62 | 51 | 100.0% | 7 | major |
| The Royal Marsden NHS Foundation Trust | 61 | 29 | 82.8% | 2 | major |
| Ferring Pharmaceuticals | 60 | 54 | 100.0% | 5 | major |
| Policlinico San Matteo | 60 | 8 | 0.0% | 39 | major |
| HOVON Foundation | 59 | 12 | 83.3% | 19 | major |
| Fondazione Giovanni Pascale | 59 | 8 | 0.0% | 22 | major |
| Sapienza University of Rome | 59 | 5 | 60.0% | 12 | major |
| Hannover Medical School | 58 | 49 | 100.0% | 3 | major |
| AOU Policlinico di Modena | 58 | 13 | 7.7% | 25 | major |
| Hvidovre Hospital | 57 | 39 | 51.3% | 8 | major |
| AOU Pisana | 57 | 5 | 0.0% | 34 | major |
| University Hospitals of Leicester NHS Trust | 56 | 45 | 97.8% | 5 | major |
| University of Hamburg | 56 | 38 | 78.9% | 0 | major |
| Belfast Health and Social Care Trust | 55 | 46 | 97.8% | 0 | major |
| Mundipharma | 55 | 46 | 93.5% | 6 | major |
| University of Antwerp | 55 | 26 | 19.2% | 9 | major |
| Skåne University Hospital | 55 | 20 | 35.0% | 11 | major |
| CHU de Nantes | 55 | 17 | 52.9% | 8 | major |
| Octapharma AG | 54 | 34 | 100.0% | 14 | major |
| King's College Hospital NHS Foundation Trust | 53 | 41 | 97.6% | 2 | major |
| Johannes Gutenberg University of Mainz | 53 | 36 | 72.2% | 7 | major |
| University of Freiburg | 53 | 30 | 86.7% | 6 | major |
| BioMarin Pharmaceutical Inc | 53 | 25 | 96.0% | 9 | major |
| Goethe University | 52 | 28 | 71.4% | 3 | major |
| Barts Health NHS Trust | 51 | 44 | 100.0% | 4 | major |
| University Hospital Southampton NHS Foundation Trust | 51 | 20 | 70.0% | 3 | major |
| Cambridge University Hospitals NHS Foundation Trust | 50 | 42 | 95.2% | 0 | major |
| Dresden University of Technology | 50 | 31 | 96.8% | 6 | major |
| Policlinico of Milan | 50 | 16 | 31.2% | 9 | major |
| PETHEMA Foundation | 50 | 7 | 28.6% | 10 | major |
| Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) | 50 | 6 | 0.0% | 29 | major |